Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -37.00p -2.16% 1,675.00p 1,672.40p 1,672.80p 1,699.20p 1,641.20p 1,696.20p 13,678,030 16:35:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 30,821.0 4,048.0 73.7 22.7 83,155

Glaxosmithkline Share Discussion Threads

Showing 19651 to 19675 of 20175 messages
Chat Pages: Latest  795  794  793  792  791  790  789  788  787  786  785  784  Older
DateSubjectAuthorDiscuss
16/5/2019
15:06
I was hoping it would drop today being ex div day so I can top up but its gone up now lol
nico9
16/5/2019
08:56
A good day, ex div almost covered :-) Lets hope it stays that way.
sicker
16/5/2019
08:22
Gaelic / Japanese translators rubbing their hands :-;
andyadvfn1
14/5/2019
09:07
All is not well at Takeda digesting Shire. "Takeda forecasts operating loss as Shire integration costs mount" hTTps://www.ft.com/content/e1d844ea-7614-11e9-be7d-6d846537acab
crossing_the_rubicon
13/5/2019
13:51
into the 14's...just days before ex div and a so called defensive stock, what a dog.
porsche1945
13/5/2019
13:26
There must be two Monties on this site. One bangs on about great dividends coming through the letterbox every 3 months and loves it. The other about the lack of growth over 20 years so a waste of time.
jadeticl3
13/5/2019
08:09
Monty - Senility strikes - your repeating yourself!
ianood
13/5/2019
08:09
Monty - ex dividend this Thursday ….. don't miss out!
tradermichael
13/5/2019
07:59
Monty - remember the figures that I provided for cumulative dividends over the same period ….. ;0)
tradermichael
12/5/2019
20:10
No growth shareprice below what it was 22 years ago.
montyhedge
12/5/2019
10:51
If 1497p fails, the next support level is 1430p I will top up, if the market allows me, somewhere close to these levels.
ny boy
12/5/2019
10:45
I will add to the portfolio if any lower, decent quarterly divi, keeps me out of mischief, meantime making the capital gains on “reach for the stars” stock - (STX)
ny boy
12/5/2019
10:32
GSK is not mentioned in the list but Pfizer is.
abdullla
12/5/2019
10:30
Spud - seems to be 'cartel like' for generics. Big business. edit: more than 100 generic drugs were included in a price-fixing scheme.
alphorn
12/5/2019
08:55
I guess we're implicated?:US states file lawsuit accusing drugs firms of inflating costs https://www.bbc.co.uk/news/world-us-canada-48241663spud
spud
10/5/2019
11:30
Negative drug pricing in US isn't helping
zipstuck
10/5/2019
10:40
Crossing, i agree, one half of it will be loaded up with debt after as well. No bounce into dividend date either, could be down 14.50 ex div. Another UK ftse terminal offender, bt, imperial, bat, banks, retailers, few growth companies, ftse filled with this going nowhere dross.
porsche1945
09/5/2019
11:56
Twitchy fingers but good news,let us hope for a steady future.
abdullla
09/5/2019
10:46
At the GSK AGM, a poll or 99.85% of shareholders voted in favour to approve the transaction between GlaxoSmithKline plc, GlaxoSmithKline Consumer Healthcare Holdings Limited and Pfizer, Inc.
tradermichael
09/5/2019
10:44
At the GSK AGM, a poll or 99.85% of shareholders voted in favour to approve the transaction between GlaxoSmithKline plc, GlaxoSmithKline Consumer Healthcare Holdings Limited and Pfizer, Inc.
tradermichael
08/5/2019
17:26
Latest US pricing side. “Drugmakers told to disclose prices in US TV ads" hTTps://www.ft.com/content/bcc244d2-7194-11e9-bbfb-5c68069fbd15
gordogecks
08/5/2019
12:51
Possible yes - likely, who knows. What's the current cash generating ability of each business? Consumer H regular. Pharms lumpy,and, a tad, irregular. And requiring substantial R&D spend at the same time.
crossing_the_rubicon
08/5/2019
12:50
CtR - yes, all about risk/reward in the main.
alphorn
08/5/2019
12:45
Not necessarily. Its possible that the Consumer Healthcare business, once floated, will take the burden of debt with it.
tradermichael
08/5/2019
12:10
GSK becomes more risky with the corporation split Emma is planning. The Pharma side becomes all the more risky, as does any divi payout associated with it, once the Consumer Biz is Ipo'd off and the corporate restructuring is complete.
crossing_the_rubicon
Chat Pages: Latest  795  794  793  792  791  790  789  788  787  786  785  784  Older
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191013 23:17:22